Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 448-100-7 | CAS number: 70441-63-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 Feb - 22 Mar 2005
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- The present study is a dose-range-finding study for a one-generation study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - Principle of test:
Exploratory, dose-range-finding study for a one-generation reproduction toxicity study. Repeated dose toxicity was assessed after 5 weeks administration of the test substance via diet.
- Short description of test conditions: Test conditions were similar to OECD TG 407 without detailed examinations.
- Parameters analysed / observed: clinical signs of toxicity, body weight, food intake, gross necropsy, organs weights of spleen, liver and kidney, histopathology of spleen, liver, and kidney - GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 448-100-7
- EC Name:
- -
- Cas Number:
- 70441-63-3
- Molecular formula:
- C9H12FN
- IUPAC Name:
- 4-fluoro-N-(propan-2-yl)aniline
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany
- Age at study initiation: about 6 weeks
- Mean body weight at study initiation: males: 146 g (range: 133 - 161 g); females: 119 g (range: 108 - 145 g)
- Housing: Animals were conventionally housed in Makrolon cages type IV on low-dust wooden granulate (Source: Ssniff Spezialdiäten Inc., Soest, Germany). Animals were group housed; 5 animals per cage. Environmental enrichment in form of wooden blocks was in place.
- Diet: fixed-formula standard diet Provimi Kliba 3883.9.25 meal (Provimi Kliba SA, Kaiseraugst, Switzerland), ad libitum
- Water: tap water in drinking water quality, ad libitum
- Acclimation period: 2 days
DETAILS OF FOOD AND WATER QUALITY
The nutritive composition and contaminant content of the standard diet were routinely checked and analyzed. The tap water complied with the current German Drinking Water Ordinance (December 1990, supplemented May 2001).
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 5
- Air changes (per hr): ≥10
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 17 Feb 2005 To: 22 Mar 2005
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: offered in diet
- Details on oral exposure:
- PREPARATION OF DOSING FORMULATION
The test substance was mixed into the diet intended for the following week according to the dose scheme. A mixing granulator (Lödige, Paderborn, Germany) was used. The mixtures were not longer used than 8 days. Stability of the test substance in the diet from 10 to 12000 ppm was demonstrated and amounts to 15 days.
DIET PREPARATION
- Rate of preparation of diet (frequency): once weekly
- Mixing appropriate amounts with (Type of food): Provimi Kliba 3883.9.25 meal
- Storage temperature of food: room temperature - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 5 weeks
- Frequency of treatment:
- continuously in the diet
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 ppm
- Remarks:
- actual test substance intake: male: 8 mg/kg bw/d; female: 10 mg/kg bw/d
- Dose / conc.:
- 500 ppm
- Remarks:
- actual test substance intake: male: 42 mg/kg bw/d; female: 48 mg/kg bw/d
- Dose / conc.:
- 2 500 ppm
- Remarks:
- actual test substance intake: male: 191 mg/kg bw/d; female: 180 mg/kg bw/d
- Dose / conc.:
- 10 000 ppm
- Remarks:
- actual test substance intake: male: 564 mg/kg bw/d; female: 470 mg/kg bw/d
- No. of animals per sex per dose:
- 5 animals/sex/dose
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: The present study was a exploratory dose-range finding study. The dose levels were selected according to results of previous studies in rats.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes.
- Time schedule: Twice daily, once daily on weekends and public holidays.
- Cage side observations checked in table (table 1) were included.
DETAILED CLINICAL OBSERVATIONS: Yes.
- Time schedule: Weekly.
BODY WEIGHT: Yes.
- Time schedule for examinations: Weekly.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each group determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No.
OPHTHALMOSCOPIC EXAMINATION: No.
HAEMATOLOGY: No.
CLINICAL CHEMISTRY: No.
URINALYSIS: No.
NEUROBEHAVIOURAL EXAMINATION: No.
IMMUNOLOGY: No. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes.
All animals sacrificed pre-scheduled or in moribund condition were killed by exsanguination under deep diethyl ether anesthesia and necropsied. Their orifices, external and internal organs and tissues were subjected to thorough gross pathological examination. Any changes were described in terms of localization, size, color, and consistency whenever present.
The organ weights of the liver, spleen, and kidneys were recorded.
HISTOPATHOLOGY: Yes.
Histopathological examinations were performed for the liver, spleen, and kidneys. - Statistics:
- Treatment groups were compared with the control group.
Statistical evaluations on body weight and organ weight data were done using the Dunnett-test in connection with a variance analysis.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At 10000 ppm all rats exhibited pallor, emaciation, and poor general condition.
No remarkable clinical findings were observed at dose levels of 2500 ppm and below. - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Because of poor general condition, all animals receiving 10000 ppm were sacrificed pre-scheduled on study day 22 (test substance administration started on study day 1).
No mortality occured at dose levels of 2500 ppm and below. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 10000 ppm, a clear body weight reduction was seen in male and female rats, which resulted in emaciation and need for pre-scheduled sacrifice.
No relevant changes in body weights were noted at dose levels of 2500 ppm and below. In fact, slightly but statistically significantly reduced or increased mean values of body weight found in males of the 100, 500, and 2500 ppm dose groups were incidential and, therefore, not toxicologically relevant (table 2). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 10000 ppm reduced food intake was observed for both sexes. As a consequence of the reduced food intake at 10000 ppm the test substance intake was less than expected in this group.
No relevant changes in food intake were observed at dose levels of 2500 ppm and below.
At doses up to 2500 ppm the test substance intake increased roughly as expected from the dose factor (table 3). - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The absolute and relative spleen weights were dose-dependently increased at 100, 500, and 2500 ppm, which was statistically significant from 500 ppm onwards (table 4).
There were no test substance-related changes in absolute and relative liver and kidney weights up to 2500 ppm. The mean relative liver weight of 100 ppm dose group males was statistically significantly reduced. However, this finding is of no toxicological relevance, because of the single occurrence and because a dose-dependency is lacking. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Blackish discoloration of the spleen (starting at 100 ppm), kidneys (starting at 500 ppm), and liver (only 10000 ppm) were noted.
At dose levels ≥ 500 ppm the spleen frequently appeared swollen and/or enlarged (500 ppm: male: 4/5, female: 5/5; 2500 ppm: male: 5/5, female: 5/5;10000 ppm: male: 4/5, female: 5/5). - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Spleen:
- Increased blood content in dilated sinuses of the red pulp in 2/5 females of the 100 ppm dose group and in all animals of the higher dosages.
- Increased extramedullary hematopoiesis at all dose levels.
- Increased deposition of a brownish pigment (most likely of ferruginous origin) at dose levels ≥ 500 ppm.
Liver:
- Pigmented Kupffer cells preferably located in the periportal areas starting in males at dose levels ≥500 ppm and in females ≥2500 ppm.
- Periportal cytoplasmic change and, in one case, periportal degeneration and bile duct proliferation at 2500 ppm.
- Centrilobular cytoplasmic change and hypertrophy in males at 500 ppm.
Kidneys:
- Deposition of a brownish pigment in all animals at 2500 ppm.
- Tubular degeneration/regeneration in 1/5 males at 2500 ppm. - Histopathological findings: neoplastic:
- not specified
Effect levels
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 100 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- gross pathology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 100 ppm
- System:
- other: spleen
- Organ:
- spleen
- Treatment related:
- yes
- Dose response relationship:
- yes
Any other information on results incl. tables
Table 2: Body weight (g)
Sex | m | m | m | m | m | f | f | f | f | f |
Dose (ppm) | 0 | 100 | 500 | 2500 | 10000 | 0 | 100 | 500 | 2500 | 10000 |
Study day | ||||||||||
1 | 143 | 144 | 147 | 147 | 149 | 120 | 117 | 120 | 121 | 118 |
8 | 163 | 171 | 172 | 174 | 129** | 140 | 140 | 141 | 136 | 107** |
15 | 178 | 190 | 190 | 201* | 127** | 156 | 160 | 157 | 153 | 105** |
22 | 239 | 214* | 210** | 224 | 125** | 175 | 176 | 168 | 164 | 100** |
29 | 233 | 227 | 223 | 240 | 181 | 185 | 175 | 170 | ||
34 | 276 | 271 | 269 | 267 | 194 | 200 | 187 | 182 |
* p ≤0.05, ** p ≤0.01
Table 3: Calculated test substance intake (mg test substance/kg body weight/day)
Sex | m | m | m | m | m | f | f | f | f | f |
Dose (ppm) | 0 | 100 | 500 | 2500 | 10000 | 0 | 100 | 500 | 2500 | 10000 |
Study day | ||||||||||
8 | - | 8 | 48 | 213 | 603 | - | 12 | 47 | 186 | 201 |
15 | - | 8 | 42 | 203 | 515 | - | 10 | 48 | 189 | 658 |
22 | - | 8 | 41 | 193 | 573 | - | 9 | 47 | 185 | 551 |
29 | - | 7 | 35 | 170 | - | 9 | 45 | 157 | ||
34 | - | 9 | 42 | 175 | - | 9 | 54 | 184 |
Table 4: Absolute and relative spleen weights
Sex | m | m | m | m | m | f | f | f | f | f |
Dose (ppm) |
0 | 100 | 500 | 2500 | 10000 | 0 | 100 | 500 | 2500 | 10000 |
Number of animals |
5 | 5 | 5 | 5 | - | 5 | 5 | 5 | 5 | - |
Final body weight (g) | 276 | 271 | 269 | 267 | 194 | 200 | 187 | 182 | ||
SPLEEN | ||||||||||
absolute weight (mg) | 575 | 614 | 821** | 1606** | 427 | 488 | 668** | 1215** | ||
relative weight (mg/100 g bw) |
208 | 227 | 307** | 602** | 219 | 245 | 358** | 668** |
* p ≤0.05, ** p ≤0.01
Applicant's summary and conclusion
- Conclusions:
- Since treatment-related effects, especially regarding the spleen, were noticed from the lowest tested dose level of 100 ppm, 100 ppm is to be considered as Lowest Observed Adverse Effect Level (LOAEL) and no No Observed Adverse Effect Level (NOAEL) could be established in the present range finding study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.